Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03899506 · ClinicalTrials.gov registry record
Olanzapine Versus Midazolam for Agitation
A clinical trial, sponsored by Hennepin Healthcare Research Institute.
- Terminated
- Registry status
- 206
- Enrollment target
NCT03899506: Clinical Trial study, sponsored by Hennepin Healthcare Research Institute.
NCT03899506 is a clinical trial that was terminated before completion, run by Hennepin Healthcare Research Institute. The registered enrollment target is 206 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03899506 was terminated before completion, sponsored by Hennepin Healthcare Research Institute.
- TERMINATED
- Registry status
- 206 participants
- Enrollment target
Study Summary
The goal of this research investigation is to conduct a prospective observation of the comparative efficacy of midazolam versus olanzapine for the treatment of acute undifferentiated agitation in the emergency department.
Primary Outcome
Proportion of patients who achieve an AMSS score of \< 1 at 15 minutes
Interventions
- DRUG Midazolam
- DRUG Olanzapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 2018-06-18 |
| Est. Completion | 2018-07-16 |
Why NCT03899506 stopped before completion
NCT03899506 is an observational study that tracks outcomes without assigning an intervention. The registered 206 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Midazolam is the first listed.
NCT03899506 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03899506 about?
NCT03899506 is a clinical study titled "Olanzapine Versus Midazolam for Agitation". The goal of this research investigation is to conduct a prospective observation of the comparative efficacy of midazolam versus olanzapine for the treatment of acute undifferentiated agitation in the emergency department.
What is the current status of trial NCT03899506?
This trial is currently terminated. The enrollment target is 206 participants. The study started on 2018-06-18. Estimated completion is 2018-07-16.
What interventions are being tested in trial NCT03899506?
The interventions under investigation include: Midazolam (DRUG), Olanzapine (DRUG).
Who is sponsoring clinical trial NCT03899506?
This trial is sponsored by Hennepin Healthcare Research Institute, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03373968 · 206 participants · Phase 2
Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
- NCT03550391 · 206 participants · Phase 3
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
- NCT04757116 · 206 participants · NA
Post-Market Study to Assess iTind Safety in Comparison to UroLift
- NCT05675865 · 206 participants · NA
Cryoablation for Monomorphic Ventricular Tachycardia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI